---
title: "Pfizer's new cancer drug Mevrometostat has initiated Phase 3 clinical trials in China, showing promising anti-cancer activity in preliminary studies"
description: "Pfizer has initiated an international multicenter Phase 3 clinical trial (MEVPRO-1) to evaluate the efficacy and safety of its new drug mevrometostat in combination with enzalutamide for patients with"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/216394907.md"
published_at: "2024-10-10T02:45:03.000Z"
---

# Pfizer's new cancer drug Mevrometostat has initiated Phase 3 clinical trials in China, showing promising anti-cancer activity in preliminary studies

> Pfizer has initiated an international multicenter Phase 3 clinical trial (MEVPRO-1) to evaluate the efficacy and safety of its new drug mevrometostat in combination with enzalutamide for patients with metastatic castration-resistant prostate cancer. The study plans to recruit 600 patients globally, including 90 from China. Mevrometostat is an EZH2 inhibitor designed to reduce cancer cell proliferation by blocking abnormal gene expression in cancer cells and inducing cell death

According to the financial news app Zhitong Finance, Pfizer (PFE.US) has recently initiated an international multicenter Phase 3 clinical trial (MEVPRO-1) in China, aiming to evaluate the efficacy and safety of PF-06821497 in combination with enzalutamide compared to enzalutamide or docetaxel in patients with metastatic castration-resistant prostate cancer who have previously received abiraterone acetate treatment. The study plans to enroll 600 participants internationally, including 90 in China.

Public information indicates that PF-06821497 (mevrometostat) is an investigational EZH2 inhibitor. According to Pfizer's disclosure during its Oncology Innovation Day in March this year, the company is expected to launch over 8 significant therapies in oncology by 2030, including this EZH2 inhibitor.

EZH2 has become one of the forefront targets in cancer treatment. EZH2 is a histone methyltransferase, and its abnormal expression is associated with the progression and poor prognosis of various cancers, including prostate, breast, lung, and hematologic malignancies. Studies have shown that overexpression of EZH2 can promote cancer initiation and progression through various mechanisms, including silencing tumor suppressor gene expression and promoting genes involved in cell proliferation and survival. Additionally, EZH2 has been shown to promote cancer metastasis by regulating gene expression involved in epithelial-mesenchymal transition.

Mevrometostat is a Pfizer-developed inhibitor targeting EZH2, which can block the abnormal gene expression in cancer cells driven by EZH2 overexpression, leading to reduced cancer cell proliferation, induced cell death, and inhibition of cancer cell migration and invasion, ultimately achieving the goal of cancer treatment.

Based on clinical data disclosed by Pfizer in March this year at the Oncology Innovation Day, the combination therapy of mevrometostat and enzalutamide (Xtandi) showed promising anti-cancer activity in a Phase 1 clinical trial for patients with metastatic castration-resistant prostate cancer (mCRPC). Specifically, in patients previously treated with abiraterone, the median radiographic progression-free survival (rPFS) with mevrometostat+enzalutamide treatment was 17.1 months, a significant improvement compared to historical data (rPFS of 4.8 months).

According to ClinicalTrials website, Pfizer initiated a Phase 3 clinical trial (MEVPRO-1 study) in the United States in August this year targeting mCRPC patients previously treated with abiraterone. This also marks Pfizer's clinical research initiation in China ![Image](https://imageproxy.pbkrs.com/http://img.zhitongcaijing.com/images/contentformat/5287161e696b069cff022bd55e0b722d.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg)

Clinical trial results of Mevrometostat (Image source: Pfizer official website)

In addition, Pfizer has recently initiated another Phase 3 study, MEVPRO-2, to evaluate mevrometostat + enzalutamide for metastatic castration-resistant prostate cancer male patients who have not been treated with abiraterone. The Investigational New Drug (IND) application for this indication has also been approved in China and is expected to start in China soon.

Studies have shown that EZH2 inhibitors have demonstrated potential in treating various types of cancers, including B-cell lymphomas, solid tumors, and certain other hematologic malignancies. For example, tazemetostat has been approved for treating some types of hematologic tumors. Meanwhile, there are multiple EZH2 inhibitors under development globally to treat various types of tumors

### Related Stocks

- [PFE.US - Pfizer](https://longbridge.com/en/quote/PFE.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 辉瑞在台湾开展新的 Elranatamab 研究，目标是收集现实世界的骨髓瘤数据 | 辉瑞公司（Pfizer Inc.，股票代码：PFE）正在台湾启动一项新的观察性研究，以评估其多发性骨髓瘤药物 elranatamab 在真实世界中的有效性。该研究旨在跟踪患者的治疗结果和治疗模式，尽管尚未开始招募参与者。此举预计将增强辉瑞的 | [Link](https://longbridge.com/en/news/276252273.md) |
| 这位辉瑞分析师以看空的基调开始覆盖；以下是周五的五大新启动 | 华尔街顶级分析师已对多家公司启动了覆盖。Baird 的 David Koning 对 Affirm Holdings (AFRM) 给予中性评级，目标价为 55 美元。Piper Sandler 的 Biren Amin 对 OKYO Ph | [Link](https://longbridge.com/en/news/276467088.md) |
| 沃尔玛四季度财报超预期但盈利指引不及预期，CEO 称 “美国低收入家庭只能勉强维持生计” | 沃尔玛 Q4 营收超预期，新财年盈利指引（每股 2.75-2.85 美元）远低于市场预期的 2.96 美元，显示通胀压力下消费者支出不确定性犹存，拖累股价下跌 1.38%。财报印证 K 型” 分化：高收入家庭驱动增长，低收入群体 “钱包吃紧 | [Link](https://longbridge.com/en/news/276398633.md) |
| 谷歌突然发布 Gemini 3.1 Pro：核心推理性能直接翻倍 | 谷歌发布了最新的大模型 Gemini 3.1 Pro，其推理性能较去年发布的 Gemini 3 Pro 翻倍。在 ARC-AGI-2 评测中，Gemini 3.1 Pro 得分 77.1%，显示出强大的推理能力。新模型支持多源数据综合和复杂 | [Link](https://longbridge.com/en/news/276396515.md) |
| 学习英伟达刺激芯片销售，AMD 为 “AI 云” 借款做担保 | AMD 为扩大市场份额祭出金融 “狠招”！为初创公司 Crusoe 的 3 亿美元购芯贷款提供担保，承诺在其无客户时 “兜底” 租用芯片。这一复刻英伟达 “租卡云” 路径的策略虽能短期推高销量，但也令 AMD 在 AI 需求放缓时面临更大的 | [Link](https://longbridge.com/en/news/276401504.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.